BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 15848559)

  • 1. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen.
    Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
    Transplant Proc; 2005 Mar; 37(2):867-70. PubMed ID: 15848559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen.
    Florman S; Alloway R; Kalayoglu M; Lake K; Bak T; Klein A; Klintmalm G; Busque S; Brandenhagen D; Lake J; Wisemandle K; Fitzsimmons W; First MR
    Transplant Proc; 2005 Mar; 37(2):1211-3. PubMed ID: 15848672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics in stable kidney transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations.
    van Hooff J; Van der Walt I; Kallmeyer J; Miller D; Dawood S; Moosa MR; Christiaans M; Karpf C; Undre N
    Ther Drug Monit; 2012 Feb; 34(1):46-52. PubMed ID: 22249344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.
    Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
    Transplantation; 2007 Jun; 83(12):1648-51. PubMed ID: 17589351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
    Nakamura Y; Hama K; Katayama H; Soga A; Toraishi T; Yokoyama T; Kihara Y; Jojima Y; Konno O; Iwamoto H; Takeuchi H; Hirano T; Shimazu M
    Transplant Proc; 2012 Jan; 44(1):124-7. PubMed ID: 22310595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-month experience with tacrolimus once-daily regimen in stable renal allografts.
    Diez Ojea B; Alonso Alvarez M; Aguado Fernández S; Baños Gallardo M; García Melendreras S; Gómez Huertas E
    Transplant Proc; 2009; 41(6):2323-5. PubMed ID: 19715908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients.
    Florman S; Alloway R; Kalayoglu M; Punch J; Bak T; Melancon J; Klintmalm G; Busque S; Charlton M; Lake J; Dhadda S; Wisemandle K; Wirth M; Fitzsimmons W; Holman J; First MR
    Transplantation; 2007 Jun; 83(12):1639-42. PubMed ID: 17589349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics in stable heart transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations.
    Alloway R; Vanhaecke J; Yonan N; White M; Haddad H; Rábago G; Tymchak W; Diaz Molina B; Grimm M; Eiskjaer H; Karpf C; Undre N
    J Heart Lung Transplant; 2011 Sep; 30(9):1003-10. PubMed ID: 21493098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients.
    Alloway RR; Eckhoff DE; Washburn WK; Teperman LW
    Liver Transpl; 2014 May; 20(5):564-75. PubMed ID: 24493215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified release tacrolimus.
    First MR; Fitzsimmons WE
    Yonsei Med J; 2004 Dec; 45(6):1127-31. PubMed ID: 15627307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First clinical experience with the new once-daily formulation of tacrolimus.
    First MR
    Ther Drug Monit; 2008 Apr; 30(2):159-66. PubMed ID: 18367975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily tacrolimus in living donor liver transplant recipients.
    Sugawara Y; Miyata Y; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Yamashiki N; Kokudo N
    Biosci Trends; 2011 Aug; 5(4):156-8. PubMed ID: 21914950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion to tacrolimus extended-release formulation: short-term clinical results.
    Gallego-Valcarce E; Ortega-Cerrato A; Llamas-Fuentes F; Martinez-Fernandez G; Perez-Martinez J; Gomez-Roldan C
    Transplant Proc; 2009; 41(6):2326-7. PubMed ID: 19715909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels.
    Crespo M; Mir M; Marin M; Hurtado S; Estadella C; Gurí X; Rap O; Moral R; Puig JM; Lloveras J
    Transplant Proc; 2009; 41(6):2115-7. PubMed ID: 19715848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients.
    Comuzzi C; Lorenzin D; Rossetto A; Faraci MG; Nicolini D; Garelli P; Bresadola V; Toniutto P; Soardo G; Baroni GS; Adani GL; Risaliti A; Baccarani U
    Transplant Proc; 2010 May; 42(4):1320-1. PubMed ID: 20534291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors.
    Meçule A; Poli L; Nofroni I; Bachetoni A; Tinti F; Umbro I; Barile M; Berloco PB; Mitterhofer AP
    Transplant Proc; 2010 May; 42(4):1317-9. PubMed ID: 20534290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation.
    Saint-Marcoux F; Debord J; Undre N; Rousseau A; Marquet P
    Ther Drug Monit; 2010 Apr; 32(2):129-35. PubMed ID: 20110850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus pharmacokinetics of once- versus twice-daily formulations in de novo kidney transplantation: a substudy of a randomized phase III trial.
    Wlodarczyk Z; Ostrowski M; Mourad M; Krämer BK; Abramowicz D; Oppenheimer F; Miller D; Dickinson J; Undre N
    Ther Drug Monit; 2012 Apr; 34(2):143-7. PubMed ID: 22406656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic study of the combination of tacrolimus and fluconazole in renal transplant patients.
    Lumlertgul D; Noppakun K; Rojanasthien N; Kanchanarattanakorn K; Jittikanont S; Manoyot A; Bunnachak D; Ophascharoensuk V
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S73-8. PubMed ID: 17044457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2015 Oct; 54(10):993-1025. PubMed ID: 26038096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.